Market Snapshot: Anti-TNFs Grow Despite Tough Market

At least one class of therapies - anti-tumor necrosis factors - is booming, even in the midst of one of the worst years financially for the pharmaceutical industry

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet